Zafrens Launches with $23M in Financing to Advance Multiple Stages of Drug Discovery in a Single Experiment at Unprecedented Scale
The financing will be used to optimize breakthrough applications of the company’s Z-Screen™ platform and advance an internal pipeline.
- The financing will be used to optimize breakthrough applications of the company’s Z-Screen™ platform and advance an internal pipeline.
- Complex cellular co-culture interactions can now be resolved at the molecular and functional levels simultaneously.
- Large CRISPR, CAR-T, mRNA libraries, or endogenous molecular heterogeneity, can be mapped to their individual manifestations as cell behavior, cell-cell interactions and secretions.
- Iterative drug discovery can now be replaced with exhaustive combinatorial profiling at extremely high resolution,” said Swamy Vijayan, CEO, Zafrens.